Compare IAC/Interactivecorp (PPLI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IAC/Interactivecorp vs Vertex Pharmaceuticals Incorporated — how do they compare? IAC/Interactivecorp trades at $37.76 (market cap $2.86B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 46.9× IAC/Interactivecorp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, IAC/Interactivecorp nearer its low. Which is the better fit depends on your goals.
| PPLI | VRTX | |
|---|---|---|
Market Cap | $2.86B | $134.06B |
Sector | Media | Health |
52-Week High | $47.62 | $557.96 |
52-Week Low | $31.52 | $376.62 |
Enterprise Value | $3.16B | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLI trades at $38.38, down 1.56% in the last session, with a bearish technical signal but attractive valuation ratios including a P/E of 6.49 and P/B of 0.56. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by gains from its MGM stake, though revenue declined to $2.39B in 2025. The company is focusing on monetizing non-core assets and capital allocation toward its media business and MGM holdings, as highlighted in recent conference presentations.
The outlook is mixed: strong analyst support with a $58.80 consensus price target and 69% buy ratings offers upside, but risks include volatile earnings, declining revenue trends, and a shareholder investigation. Investors should weigh the deep valuation discount against execution challenges in asset sales and digital growth.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
